Primmune Therapeutics
Debora Dumont is an accomplished professional with extensive experience in the life sciences and healthcare sectors. Currently serving as a Board Member at Primmune Therapeutics and Anavo Therapeutics BV, and as a Director at Enhanc3D Genomics Ltd, Debora also co-founded and manages Bioqube Ventures. Previous roles include being a Bestuurder at LIMBURGS KANKERFONDS and Director at BioVille - LSDC NV, along with leadership positions at LRM and Hasselt University-BIOMED. Debora holds a PhD in Biomedical Sciences from Hasselt University and a degree in Bioscience Engineering, specializing in Cell and Gene Technology from KU Leuven.
This person is not in the org chart
This person is not in any offices
Primmune Therapeutics
1 followers
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.